aromasil has been researched along with toremifene in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Eckhardt, S | 1 |
| Ohtake, T; Okayama, H; Sagara, H; Takenoshita, S; Watanabe, K; Yasuda, M | 1 |
| Suzuki, M | 1 |
| Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S | 1 |
| Aogi, K; Hara, F; Kiyoto, S; Osumi, S; Takabatake, D; Takashima, S | 1 |
| Chishima, T; Hozumi, Y; Ikeda, M; Ishikawa, T; Iwase, H; Iwata, H; Saji, S; Toyama, T; Yamamoto, Y; Yamamoto-Ibusuki, M; Yamashita, H | 1 |
| Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W | 1 |
| Chaiyakunapruk, N; Imanaka, Y; Kunisawa, S; Lertjanyakun, V | 1 |
| Chen, J; Fan, Y; He, T; Huang, Q; Li, P; Lv, Q; Wu, Y; Xiang, M; Yang, D; Yang, W; Zhang, X; Zhou, R | 1 |
3 review(s) available for aromasil and toremifene
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles | 2003 |
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Letrozole; Lipids; Network Meta-Analysis; Research Design; Tamoxifen; Toremifene | 2020 |
1 trial(s) available for aromasil and toremifene
| Article | Year |
|---|---|
Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prognosis; Receptors, Estrogen; Survival Rate; Toremifene | 2013 |
7 other study(ies) available for aromasil and toremifene
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
[A patient with metastatic breast cancer associated with retention of pleural effusion with no response to both CMF and exemestane, whose life was saved by high-dose toremifene].
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Pleural Effusion; Remission Induction; Salvage Therapy; Toremifene | 2005 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Pleural Effusion, Malignant; Pleural Neoplasms; Quality of Life; Remission Induction; Taxoids; Toremifene | 2007 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cortisone; Cyclophosphamide; Diphosphonates; Docetaxel; Fatal Outcome; Fluorouracil; Furosemide; Humans; Imidazoles; Liver Neoplasms; Male; Mandibular Neoplasms; Mastectomy, Modified Radical; Methotrexate; Omeprazole; Osteolysis; Phenobarbital; Taxoids; Toremifene; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
[A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy].
Topics: Androstadienes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Letrozole; Liver Neoplasms; Medroxyprogesterone; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Toremifene; Triazoles | 2009 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles | 2014 |
Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Everolimus; Female; Fulvestrant; Health Care Costs; Humans; Japan; Markov Chains; Middle Aged; Models, Economic; Postmenopause; Quality-Adjusted Life Years; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Toremifene | 2018 |